Search research articles
Contact Us
Filters
Showing results (11-20 of 134) with videos related to
Page
of 14
Sort By:
Leukemia
|
January 13, 2024
How to individualize therapy after failing milestones in chronic myeloid leukaemia: weighting late response and early death from CML against risk of alternative therapies
Rüdiger Hehlmann, Michael Lauseker
Blood
|
November 1, 2024
Long-term outcomes of tyrosine kinase inhibitors in chronic myeloid leukemia
François Guilhot, Rüdiger Hehlmann
Annals of Hematology
|
June 3, 2005
Chronic myeloid leukemia: a model for oncology
Rüdiger Hehlmann, Ute Berger, Andreas Hochhaus
Seminars in Thrombosis and Hemostasis
|
May 5, 2006
Diagnosis and therapy of polycythemia vera
Eva Lengfelder, Kirsten Merx, Rüdiger Hehlmann
Annals of Hematology
|
March 28, 2015
The interferon-alpha revival in CML
Moshe Talpaz, Jessica Mercer, Rüdiger Hehlmann
Lancet (London, England)
|
July 31, 2007
Chronic myeloid leukaemia
Rüdiger Hehlmann, Andreas Hochhaus, Michele Baccarani, et al.
Expert Opinion on Pharmacotherapy
|
January 14, 2011
Treatment of chronic myeloid leukemia when imatinib fails
Rüdiger Hehlmann, Susanne Jung-Munkwitz, Susanne Saussele
Bone Marrow Transplantation
|
April 10, 2020
Clara Bloomfield MD: Queen of AML. Dare to cross her at your risk (May 15, 1942 to March 1, 2020)
Robert Peter Gale, Rüdiger Hehlmann, Andreas Hochhaus
Journal of Critical Care
|
October 16, 2004
Management of infections in critically ill neutropenic cancer patients
Dieter Buchheidt, Margit Hummel, Georg Engelich, et al.
European Journal of Haematology
|
April 3, 2004
Fatal cerebral involvement in systemic aspergillosis: a rare complication of steroid-treated autoimmune bicytopenia
Dieter Buchheidt, Margit Hummel, Steffen Diehl, et al.
Page
of 14
Search research articles
Search
Showing results (11-20 of 134) with videos related to
Sort By:
Page
of 14
Leukemia
|
January 13, 2024
How to individualize therapy after failing milestones in chronic myeloid leukaemia: weighting late response and early death from CML against risk of alternative therapies
Rüdiger Hehlmann, Michael Lauseker
Blood
|
November 1, 2024
Long-term outcomes of tyrosine kinase inhibitors in chronic myeloid leukemia
François Guilhot, Rüdiger Hehlmann
Annals of Hematology
|
June 3, 2005
Chronic myeloid leukemia: a model for oncology
Rüdiger Hehlmann, Ute Berger, Andreas Hochhaus
Seminars in Thrombosis and Hemostasis
|
May 5, 2006
Diagnosis and therapy of polycythemia vera
Eva Lengfelder, Kirsten Merx, Rüdiger Hehlmann
Annals of Hematology
|
March 28, 2015
The interferon-alpha revival in CML
Moshe Talpaz, Jessica Mercer, Rüdiger Hehlmann
Lancet (London, England)
|
July 31, 2007
Chronic myeloid leukaemia
Rüdiger Hehlmann, Andreas Hochhaus, Michele Baccarani, et al.
Expert Opinion on Pharmacotherapy
|
January 14, 2011
Treatment of chronic myeloid leukemia when imatinib fails
Rüdiger Hehlmann, Susanne Jung-Munkwitz, Susanne Saussele
Bone Marrow Transplantation
|
April 10, 2020
Clara Bloomfield MD: Queen of AML. Dare to cross her at your risk (May 15, 1942 to March 1, 2020)
Robert Peter Gale, Rüdiger Hehlmann, Andreas Hochhaus
Journal of Critical Care
|
October 16, 2004
Management of infections in critically ill neutropenic cancer patients
Dieter Buchheidt, Margit Hummel, Georg Engelich, et al.
European Journal of Haematology
|
April 3, 2004
Fatal cerebral involvement in systemic aspergillosis: a rare complication of steroid-treated autoimmune bicytopenia
Dieter Buchheidt, Margit Hummel, Steffen Diehl, et al.
Page
of 14